Richard Brudnick - Feb 16, 2022 Form 4 Insider Report for Codiak BioSciences, Inc. (CDAKQ)

Role: Officer title: Chief Business Officer and Head of Corporate Strategy
Signature: /s/ Yalonda Howze, Attorney-in-Fact for Richard Brudnick
Stock symbol: CDAKQ
Transactions as of: Feb 16, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/18/2022, 03:05 PM
Previous filing: Jan 21, 2022
Next filing: Apr 8, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CDAKQ	Stock Option (Right to Buy)	Award	$0	+10.9K		$0.00	10.9K	Feb 16, 2022	Common Stock	10.9K	$5.21	Direct	F1
transaction	CDAKQ	Restricted Stock Units	Award	$0	+16.3K		$0.00	16.3K	Feb 16, 2022	Common Stock	16.3K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of this option shall vest and become exercisable on February 16, 2023, with the remainder vesting in 12 equal quarterly installments thereafter.
F2	Each restricted stock unit represents a contingent right to receive one share of common stock.
F3	On February 16, 2022, the reporting person was granted 16,275 restricted stock units, vesting in four equal installments every six months beginning on the six month anniversary of the grant date.

Remarks:

Officer title: Chief Business Officer and Head of Corporate Strategy